{"id":4465,"date":"2022-02-07T11:11:40","date_gmt":"2022-02-07T10:11:40","guid":{"rendered":"https:\/\/ibb.uab.cat\/?p=4465"},"modified":"2022-02-07T11:11:41","modified_gmt":"2022-02-07T10:11:41","slug":"nanoligent-sl-capta-1-milio-deuros-en-financament-llavor","status":"publish","type":"post","link":"https:\/\/ibb.uab.cat\/index.php\/2022\/02\/07\/nanoligent-sl-capta-1-milio-deuros-en-financament-llavor\/","title":{"rendered":"Nanoligent SL capta 1 mili\u00f3 d\u2019euros en finan\u00e7ament llavor"},"content":{"rendered":"\n<div class=\"wp-block-image\"><figure class=\"alignleft size-large is-resized\"><img loading=\"lazy\" src=\"https:\/\/ibb.uab.cat\/wp-content\/uploads\/Nanoligent_seedRound-1024x1024.png\" alt=\"\" class=\"wp-image-4461\" width=\"467\" height=\"467\" srcset=\"https:\/\/ibb.uab.cat\/wp-content\/uploads\/Nanoligent_seedRound-1024x1024.png 1024w, https:\/\/ibb.uab.cat\/wp-content\/uploads\/Nanoligent_seedRound-300x300.png 300w, https:\/\/ibb.uab.cat\/wp-content\/uploads\/Nanoligent_seedRound-150x150.png 150w, https:\/\/ibb.uab.cat\/wp-content\/uploads\/Nanoligent_seedRound-768x768.png 768w, https:\/\/ibb.uab.cat\/wp-content\/uploads\/Nanoligent_seedRound-100x100.png 100w, https:\/\/ibb.uab.cat\/wp-content\/uploads\/Nanoligent_seedRound-260x260.png 260w, https:\/\/ibb.uab.cat\/wp-content\/uploads\/Nanoligent_seedRound.png 1080w\" sizes=\"(max-width: 467px) 100vw, 467px\" \/><\/figure><\/div>\n\n\n\n<p><a href=\"http:\/\/www.nanoligent.com\/\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>Nanoligent SL<\/strong><\/a><strong>, empresa especialitzada en el desenvolupament de tractaments contra el c\u00e0ncer basats en nanotecnologia, capta 1M\u20ac<\/strong> en una ronda de finan\u00e7ament inicial per completar el desenvolupament precl\u00ednic d\u2019aquesta tecnologia en diferents tipus de tumors i poder-se apropar al mercat per aquells candidats m\u00e9s prometedors.&nbsp;&nbsp;<\/p>\n\n\n\n<p>Nanoligent SL \u00e9s una empresa spin-off biotecnol\u00f2gica fundada l&#8217;any 2017 gr\u00e0cies a la fruct\u00edfera <strong>col\u00b7laboraci\u00f3 durant m\u00e9s d&#8217;una d\u00e8cada entre el Grup de Nanobiotecnologia de l&#8217;IBB, liderat per Antonio Villaverde, i el Grup d\u2019Investigaci\u00f3 en Oncog\u00e8nesis i Antitumorals de l&#8217;IIB Sant Pau, dirigit per Ramon Mangues<\/strong>.&nbsp;<\/p>\n\n\n\n<p>La ronda de finan\u00e7ament ha estat liderada per membres d&#8217;Italian Angels for Growth, la xarxa m\u00e9s gran de business angels d&#8217;It\u00e0lia, a trav\u00e9s del vehicle d&#8217;inversi\u00f3 Nanolinvest, i AVANTECA Partners, una empresa privada de gesti\u00f3 d&#8217;actius su\u00efssa, ambdues especialitzades en donar suport a empreses innovadores en fase inicial de vida. Una campanya d&#8217;equitat, encara est\u00e0 en curs a <a href=\"https:\/\/www.doorwayplatform.com\/en\" target=\"_blank\" rel=\"noreferrer noopener\">Doorway<\/a>, una plataforma d&#8217;inversi\u00f3 en l\u00ednia, prometent aix\u00ed proporcionar finan\u00e7ament addicional per a l&#8217;empresa. <strong>Aquesta injecci\u00f3 de capital&nbsp; suposar\u00e0 un pas endavant per seguir desenvolupant una nova ter\u00e0pia oncol\u00f2gica basada en un nanocompost capa\u00e7 d&#8217;interferir en la proliferaci\u00f3 metast\u00e0tica de diferents tipus de tumors.<\/strong>&nbsp;<\/p>\n\n\n\n<p>Esther V\u00e1zquez i Antonio Villaverde, investigadors de l\u2019IBB que sempre estan compromesos amb la investigaci\u00f3 d&#8217;impacte, s\u00f3n els cofundadors i assessors cient\u00edfics de Nanoligent, i els felicitem per aquesta fita tan not\u00f2ria que han aconseguit. &nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Nanoligent SL, empresa especialitzada en el desenvolupament de tractaments contra el c\u00e0ncer basats en nanotecnologia, capta 1M\u20ac en una ronda de finan\u00e7ament inicial per completar el desenvolupament precl\u00ednic d\u2019aquesta tecnologia en diferents tipus de tumors i poder-se apropar al mercat per aquells candidats m\u00e9s prometedors.&nbsp;&nbsp; Nanoligent SL \u00e9s una empresa spin-off biotecnol\u00f2gica fundada l&#8217;any 2017 [&hellip;]<\/p>\n","protected":false},"author":65,"featured_media":4461,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[4],"tags":[],"_links":{"self":[{"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/posts\/4465"}],"collection":[{"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/users\/65"}],"replies":[{"embeddable":true,"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/comments?post=4465"}],"version-history":[{"count":1,"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/posts\/4465\/revisions"}],"predecessor-version":[{"id":4466,"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/posts\/4465\/revisions\/4466"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/media\/4461"}],"wp:attachment":[{"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/media?parent=4465"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/categories?post=4465"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/tags?post=4465"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}